Solesence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, announced its financial results for the fourth quarter and year ended December 31, 2025. The company achieved record revenue of $62.1 million for the full year, marking a 19% increase from $52.3 million in 2024. This growth is attributed to the successful launch of new products and the expansion of its consumer product line, which has effectively doubled in just two years. In the fourth quarter, revenue was reported at $12.5 million, slightly down from $12.6 million in the same period last year, but gross profit increased to $3.4 million, up from $2.8 million in 2024, reflecting improved gross margins. The company also reported a net income of approximately $1.8 million for the full year, a decrease from $4.2 million in 2024, primarily due to increased operational expenses associated with its growth initiatives. CEO Kevin Cureton emphasized the importance of the 'Transform & Transcend' initiative launched in November, which aims to align operational execution with the company's rapid growth and capitalize on its market position. CFO Laura Riffner expressed confidence in the company's ability to meet its objectives for 2026, highlighting strong momentum from organizational changes and the new strategic initiative. The company plans to host a conference call to discuss these results further, inviting stakeholders to join and engage with the leadership team.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.